

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b> 49D0933746	<b>(X3) Date Survey Completed</b> 07/20/2020
<b>Name of Provider or Supplier</b> Community Health Clinic Pc	<b>Street Address, City, State</b> 5705 Redbud Hwy, Honaker, VA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D0000</b>	An unannounced CLIA off-site paper proficiency testing (PT) desk review survey of Community Health Clinic (Honaker) on July 20, 2020 was conducted by a Medical Facilities Inspector of the Virginia Department of Health's Office of Licensure and Certification. The laboratory was inspected under 42 CFR Part 493 CLIA regulations. The laboratory of Community Health Clinic (Honaker) is not in compliance with applicable Conditions and related Standards of 42 CFR Part 493 CLIA Requirements. Review of the Medical Laboratory Evaluation (MLE) 2nd event hematology scores and the CASPER 0155 Individual Laboratory Profile for PT scores revealed that the laboratory received 100% for the White Blood Cell Differential (WBC DIFF). The laboratory must achieve satisfactory performance of at least 80% for two consecutive events for the White Blood Cell Differential (WBC DIFF). Third event score review to follow for 2020.
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor</p>

compliance history.

This CONDITION is not met as evidenced by:

The laboratory of Community Health Clinic (Honaker) is not in compliance with applicable Conditions and related Standards of 42 CFR Part 493 CLIA Requirements. Review of the Medical Laboratory Evaluation (MLE) 2nd event hematology scores and the CASPER 0155 Individual Laboratory Profile for PT scores revealed that the laboratory received 100% for the White Blood Cell Differential (WBC DIFF). Refer to D2130. The laboratory must achieve satisfactory performance of at least 80% for two consecutive events for the White Blood Cell Differential (WBC DIFF). Third event score review to follow for 2020.

**D2130**

**HEMATOLOGY**

CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on the off-site desk review proficiency testing (PT) scores to include the Medical Laboratory Evaluation (MLE) hematology PT scores, the CASPER 0155 Individual Laboratory Profile for PT scores and the CASPER 0153D Unsuccessful PT report revealed the following scores: 2019 3rd event WBC Diff- 0% 2020 1st event WBC Diff- 0% 2020 2nd event WBC Diff- 100% The laboratory must achieve satisfactory performance of at least 80% for two consecutive events for the White Blood Cell Differential (WBC DIFF). Third event score review to follow for 2020.